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Summary. Background: Little research has been performed
regarding thepsychological consequencesofknowingthatone is
at an increased risk for venous thrombosis. Objectives:The aim
of this study was to explore attitudes toward genetic testing for
protein C deﬁciency. Methods: Questionnaires about genetic
testing attitudes, dispositional anxiety, risk perception, and
thrombosis-relatedworrywere completedby168asymptomatic
members of aNorth-American kindredwith a high incidence of
heritable protein C deﬁciency conferring a high lifetime risk of
venous thrombosis. A total of 76 subjects (45%) had not been
tested for protein C deﬁciency before participating in our study
whereas the other 92 subjects (55%) had been tested prior to
ﬁlling in the questionnaire, of whom 34 people had protein C
deﬁciency, while 58 did not. Results: Family members with
protein C deﬁciency perceived a higher risk of suﬀering venous
thrombosis and scored higher on thrombosis-related worry
than familymembers without protein C deﬁciency. Participants
who had not been tested did not report excessive thrombosis-
related worry. Participants with protein C deﬁciency reported a
belief in the psychological and health beneﬁts of testing, and felt
that they experienced low psychological distress following the
genetic test. High psychological distress following the test was
related to dispositional anxiety and thrombosis-related worry.
Participants without protein C deﬁciency were relieved
after ﬁnding out that they did not have the deﬁciency.
Conclusion: There seem to be few negative psychological con-
sequences of knowing that one is at an increased risk for venous
thrombosis, except in vulnerable individuals.
Keywords: genetic testing, protein C deﬁciency, psychology,
risk perception, screening, thrombophilia.
Background
The number of inherited disorders and risk factors that can
be detected through genetic testing is increasing rapidly, and
genetic testing is becoming a common component of routine
medical care. Recently, genetic testing is being applied to
detect personal susceptibility to disease, in the belief that
awareness of genetic risk will enhance informed medical
decision making and have an impact on changing health
behavior [1].
Quality of life in patients with venous thrombosis is impaired
compared with a healthy population, especially in the presence
of the post-thrombotic syndrome. This impairment encompas-
ses the physical, social and psychological domains of quality of
life [2,3]. Venous thrombosis is a multi-causal disease caused by
both genetic and acquired risk factors [4,5]. Examples of
acquired risk factors are older age, the use of oral contracep-
tives, hormone replacement therapy, pregnancy, and immobil-
ization. The discovery of genetic risk factors for venous
thrombosis, and the widespread clinical application of genetic
screening, has engendered a debate regarding the pros and cons
of thrombophilia testing [6,7]. Generally, it is believed that
widespread screening for thrombophilia is not justiﬁed because
it is not cost-effective. However, some believe screening of
patients at a high risk of venous thrombosis is likely to be useful
because it may improve clinical outcome through changes in
the appropriate use and duration of therapy. It is reasoned that
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family screening of individuals with a close relative with
thrombophilia can help optimize prophylactic treatment of
asymptomatic carriers in high-risk situations (i.e. during
surgery or pregnancy in which they would normally not receive
treatment) [8]. To date, there are no data supporting this view.
Opponents of widespread screening have pointed out that it
may lead to psychological distress. However, little research has
focused on the psychological consequences of knowing that one
is at an increased risk for venous thrombosis. This is notable
because carriership of a genetic deﬁcit may inﬂuence daily life,
as it can cause considerable distress. Research on the psycho-
logical inﬂuence of genetic testing has focused mainly on single
gene conditions such as Huntington’s disease, and on hered-
itary cancers. Findings suggest that individuals undergoing
predictive genetic testing do not experience considerable long-
term psychological distress [9,10]. However, individuals with a
high predisposition to depression or anxiety may be more
vulnerable to adverse effects [1,11]. Possible negative effects of a
positive test result include anxiety and depression following the
test, worry about the future and about the possibility of passing
the genetic defect on to children. Furthermore, positive test
results might cause stigmatization, problems with insurance,
and they can interfere with medical decision making. To our
knowledge, only three previous publications have dealt with the
subject of the social and psychological impact of awareness of
carriership of thrombophilia. The ﬁrst study investigated
women’s reactions to awareness of activated protein C (APC)
resistance carriership in 270 women [12]. In this study, women
were asked to answer questions about the way their knowledge
of APC resistance has affected them, in a yes/no format. The
study concluded that most women were pleased with having
been informed of their status. The majority of women (84%)
found that their awareness of APC resistance might be an
advantage in the event of future operations or accidents, and
69% reported that their lives were unaffected by the knowledge
of APC resistance. However, 27% of the women reported that
they had become more worried, and 10% was afraid to get
pregnant again. The second study, byHellmann et al. [13], used
a questionnaire with a Likert scale to examine patient
experience of genetic testing for factor V Leiden (FVL) in 110
patients and found that 43% of the patients experienced
increased worry. In addition, they reported that patients
indicated concern with the lack of available information about
FVL. The discrepancy in the reported worry rates of these two
studies might be explained by the difference in methodology
between the two studies. ALikert scale allows participants to be
more speciﬁc in their responses, rather than having to choose
between two endpoints in a yes/no format.
The third study on this subject explored the psychological
and social aspects of asymptomatic carriership of the FVL
mutation in a qualitative study. After interviewing 17 individ-
uals, the authors concluded that carriership of FVL has the
potential to inﬂuence daily life by inducing concerns, stigmat-
ization and problems with insurance eligibility [14].
The results of these three studies need to be replicated
and clariﬁed in more structured studies, which assess the
psychological impact of genetic testing for thrombophilia and
factors that might inﬂuence this impact.
Protein C is a vitamin K-dependent protein that, upon
activation toAPC, inhibits thrombus formation by inactivating
the coagulation factors Va and VIIIa. Deﬁciency of protein C
was one of the ﬁrst genetic risk factors associated with
hereditary thrombophilia [15]. The lifetime risk for venous
thrombosis in protein C deﬁcient individuals is about 10-fold
increased compared with the normal population [16]. Protein C
deﬁciency is caused by a wide variety of mutations in the
protein C gene. The present study investigates a large kindred
of French–Canadian descent with protein C deﬁciency caused
by a 3363 C insertion mutation [17].
The aim of this study was to explore the attitudes of
protein C deﬁcient individuals about genetic testing and to
assess their perception of their thrombotic risk and their
thrombosis-related worry. Furthermore, we tried to establish
the role of trait anxiety in these attitudes to test the
hypothesis that, as in earlier research on predictive genetic
testing, individuals with a higher psychological vulnerability
experience more psychological distress following the genetic
test. Age and sex differences were assessed because older age
and female hormones are risk factors for venous thrombo-
sis. In addition, we assessed the knowledge of participants
about other risk factors for venous thrombosis, and the
relationship of this knowledge with risk perceptions, throm-
bosis-related worry and attitudes about genetic testing.
Method
Participants
The ascertainment and evaluation of the family members
participating in this study were described previously [18].
Members of the kindred were contacted by phone by one of
the investigators (SN) and an appointment was made to
meet with the investigators. At this appointment, several
questionnaires were completed. All participating subjects
gave informed consent. The study protocol was approved by
the Human Experimentation Committee of the University of
Vermont College of Medicine, Burlington (VT, USA).
Inclusion criteria stipulated that participants had to be over
age 18, and physically and mentally capable of completing
the questionnaire. Participants were divided into three
groups: participants who had not been tested before (group
1), participants with protein C deﬁciency (group 2), and
participants without protein C deﬁciency (group 3). Most of
the participants who were tested before (group 2 and 3)
were tested in a previous study [18].
Measurements
All participants
Risk perception Perceived risk of venous thrombosis was
assessed with two items:
2438 I. M. van Korlaar et al
 2005 International Society on Thrombosis and Haemostasis
(i) How likely do you think it is that, at some point in your life,
you will get thrombosis?
(ii) How vulnerable do you think you are to getting thrombosis
at some point in your life? Each item was rated on a seven-
point Likert scale ranging from one (not at all) to seven
(almost certain or extremely) and summed to generate risk
perception scores.
Worry Worry about venous thrombosis was assessed with
two items: (i) To what extent are you worried about getting
thrombosis? (ii) To what extent are you concerned about
getting thrombosis? Each item was rated on a seven-point
Likert scale ranging from one (not at all) to seven (extremely)
and summed to generate worry scores.
Trait anxiety As a measure of dispositional anxiety, the
trait form of the State-Trait Anxiety Inventory (STAI) (form
Y-2) was included [19]. This is a 20-item questionnaire that
measures relatively stable individual differences in anxiety
proneness. All items are rated on a scale from one (not at all) to
four (very much so).
Knowledge about risk factors for venous thrombosis To
assess the knowledge of participants about the acquired risk
factors for venous thrombosis, a scale with eight items was
used, on which participants had to rate on a ﬁve-point Likert
scale (ranging from strongly disagree to strongly agree) whether
they believed this risk factor could cause venous thrombosis or
not. The scale consisted of the following items: pregnancy or
child birth, birth control pills, bed rest, lack of exercise, sitting
for long periods, surgery, aging, accident or injury. To calculate
a score for the knowledge about risk factors for venous
thrombosis, we assigned one point to each item that participant
agreed or strongly agreedwith, and points were added (possible
score range 0–8).
Group 1: Participants who had not been tested before and
group 2: Protein C deﬁcient participants
Attitudes about testing To assess the attitudes about getting
a genetic test for protein C deﬁciency in both family
members that had been tested positive for protein C
deﬁciency and family members that had not been tested
before, attitude scales were adapted from a study by
Cameron et al. [20], in which the same attitude scales were
being applied to assess beliefs about testing for breast cancer
susceptibility. Both groups completed a similar set of the
following items, appropriate to their status. For group 2,
items referred to how individuals felt about the genetic test
result now, rather than how they felt when they had just
received the results.
Health beneﬁts beliefs were assessed with a set of ﬁve items
(e.g. knowing whether I have protein C deﬁciency or not would
give me more control over my health; knowing that I have
protein C deﬁciency gave me more control over my health).
These items were all rated on a Likert scale ranging from zero
(strongly disagree) to six (strongly agree) and summed to
generate health beneﬁts beliefs scores.
Psychological beneﬁts beliefs were assessed with four items
(e.g. the test would reduce the anxiety of not knowing one’s
genetic background; the test reduced the anxiety of not
knowing my genetic background). These items were all rated
on a Likert scale ranging from zero (strongly disagree) to six
(strongly agree) and summed to generate psychological beneﬁts
beliefs scores.
Psychological distress beliefs were assessed with ﬁve items
(e.g. knowing that I have protein C deﬁciency would seriously
harm my self-image; knowing that I have protein C deﬁciency
seriously harmed my self-image). These items were all rated on
a Likert scale ranging from zero (strongly disagree) to six
(strongly agree) and summed to generate psychological distress
beliefs scores.
Furthermore, participants who had not been tested before
(group 1) ﬁlled in two items about their interest in getting a
genetic test and their beliefs in the likelihood of receiving a
positive test result.
Testing interest Interest about getting the genetic test for
protein C deﬁciency was assessed with one item: how interested
are you in getting a genetic test for protein C deﬁciency? This
item was rated on a seven-point Likert scale ranging from one
(not at all interested) to seven (extremely interested).
Likelihood of having protein C deﬁciency With one item,
the belief in the likelihood of receiving a positive test result was
assessed: if you would be tested, how likely do you think it is
that you have protein C deﬁciency? This item was rated on a
seven-point Likert scale ranging from one (not at all) to seven
(almost certain).
Group 3: Participants without protein C deﬁciency Three
additional items were added for participants who tested
negative for protein C deﬁciency. All items were rated on a
seven-point Likert scale ranging from one (not at all) to seven
(extremely).
Relief One item assessed the amount of relief the
participants felt after ﬁnding out that they did not have
protein C deﬁciency: did you feel relieved after ﬁnding out that
you do not have protein C deﬁciency?
Guilt One item assessed whether participants felt guilty
about not having protein C deﬁciency: if other people in your
family have protein C deﬁciency, did you feel guilty after
ﬁnding out that you do not have it?
Likelihood of having protein C deﬁciency if tested
again One item assessed the false or correct beliefs of
participants about the likelihood of getting a positive test
result, if they would be tested again: if you would be tested
again, how likely do you think it is that you have protein C
deﬁciency?
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Results
Demographic variables
A total of 265 family members were invited to participate in the
study.Of the non-responders, 30 (11.3%) refused to participate,
22 (8.3%) did not show up at their scheduled appointment,
and 15 (5.7%) could not participate because of other reasons
such as illness. A questionnaire was eventually ﬁlled out by
198 (74.7%) family members. Questionnaires of 24 participants
who had already suffered from venous thrombosis were
removed from the present analyses because the aim of this
paper was to study attitudes about genetic testing in thrombo-
philic individuals without a history of venous thrombosis.
A further six questionnaires were removed because of
incomplete data. The remaining database consisted of 168
participants. The mean age of the participants was 44.4 (SD
14.2) years with a range from 18 to 76 years. The sample
consisted of 73 men (43%) and 95 women (57%). Of all
participants, 92 subjects (55%) had been tested for protein C
deﬁciency in a previous study [18], and 76 subjects (45%) had
not been tested before and thus did not know their status when
they completed the questionnaires. Of the tested participants,
34 people had protein C deﬁciency, and 58 participants had
tested negative.
Descriptive analyses
In further analyses, a distinction was made among the three
groups of participants: participants who had not been tested
(group 1), participants with protein C deﬁciency, and parti-
cipants without protein C deﬁciency. Internal consistency of all
attitude scales was satisfactory (Cronbach’s alpha’s > 0.70)
and the items from the risk perception and worry scores were
highly correlated (r ¼ 0.90 and r ¼ 0.87). To test for age
differences, a median split of the sample was made (median ¼
45). To protect against inﬂation of type 1 error from multiple
correlations and other statistical tests, we usedP < 0.01 as our
critical value for all statistical tests.
Group 1: Participants who had not been tested before
(n ¼ 76)
Table 1 presents means, SDs and intercorrelations among all
measures, for participants that had not been tested for protein
C deﬁciency.Means for risk perception and thrombosis-related
worry were 3.9 and 3.4 on scales ranging from 2 to 14,
indicating that participants did not think it is very likely that
they would ever get venous thrombosis or worry a lot about it.
Mean scores on beliefs in the health beneﬁts and psychological
beneﬁts of testing were 20.6 and 15.1 on scales ranging from 0
to 30 and 0 to 24, whereas the belief in psychological distress
following the genetic test was 7.5 on a scale ranging from 0 to
30. This indicates that beliefs about the positive consequences
of getting a genetic test were stronger than beliefs about the
negative consequences of the test. For the beneﬁts of testing,
the itemwith the highest mean score was I should get tested for
the sake of my family and loved ones (mean 4.7), indicating
that deciding to have a genetic test for protein C deﬁciency is
primarily a matter of concern for the family. The item with the
lowest mean score was The test results would help me in
making decisions about whether and when to have children
(mean 0.7). The mean score on the trait form of the STAI was
36.3 (SD 9.6). Participants were quite interested in getting a
genetic test for protein C deﬁciency (mean 4.6 on a scale
ranging from 1 to 7) and did not think it was very likely that
they would have protein C deﬁciency (mean 2.6 on a scale from
1 to 7). Risk perception and worry were correlated (r ¼ 0.51,
P < 0.01). Higher trait anxiety was related to a higher belief in
psychological distress following the test (r ¼ 0.37, P < 0.01),
but not to a higher interest in getting the test, or a higher belief
that one will have protein C deﬁciency. Beliefs in higher health
and psychological beneﬁts of testing were correlated with more
interest in getting the genetic test (r ¼ 0.59 and 0.46,P < 0.01)
and a belief that one will have protein C deﬁciency (r ¼ 0.35
and 0.41, P < 0.01). Older participants had higher scores on
thrombosis-related worry than younger participants
(P < 0.01). No sex differences could be detected.
Group 2: Participants with protein C deficiency (n ¼ 34)
Table 2 presents means, SDs and intercorrelations among all
measures for participants who previously had been tested
positive for protein C deﬁciency. Risk perception and throm-
bosis-related worry were higher than risk perception and worry
scores for participants who had not been tested (means 5.4 and
5.5 on scales ranging from 2 to 14). Beliefs in the health
beneﬁts, psychological beneﬁts and psychological distress
following the test were marginally lower than the beliefs of
participants who had not been tested (means 19.4, 14.3 and 5.3
on scales ranging from 0 to 30, 0 to 24 and 0 to 30). For the
health and psychological beneﬁts of testing, the item with the
highest mean score was again I got tested for the sake of my
family and loved ones (mean 4.6 on a scale ranging from 1 to
7). Furthermore, the itemwith the lowest mean score was again
The test results helped me in making decisions about whether
and when to have children (mean 1.6 on a scale ranging from
1 to 7). The mean score on the trait form of the STAI was 32.9
(SD 9.0). Risk perception and worry were correlated (r ¼ 0.70,
P < 0.01). Beliefs in health beneﬁts and psychological beneﬁts
following the genetic test were also related (r ¼ 0.60,
P < 0.01). Both thrombosis-related worry and trait anxiety
were correlated with psychological distress following the
genetic test (r ¼ 0.52 and r ¼ 0.61, P < 0.01). There were
no sex or age differences for any of the measures.
Group 3: Participants without protein C deficiency (n ¼ 58)
Table 3 presents intercorrelations among all measures, means
and SDs, for patients who had been tested negative for
protein C deﬁciency. In this group, risk perception and
thrombosis-related worry were lower than in the other groups
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and correlated as well (means 3.2 and 3.2 on scales ranging
from 2 to 14, r ¼ 0.62, P < 0.01). The mean score on the
trait form of the STAI was 32.5 (SD 9.4). More than half of
the participants (61%) reported that they felt relieved after
ﬁnding out that they did not have protein C deﬁciency and
the majority (81%) did not feel guilty when other family
members were tested positive. Furthermore, most participants
(87%) correctly assumed that a second test would still be
negative. A higher risk perception or worry about getting
thrombosis was associated with a higher belief that a second
test would give a positive result (r ¼ 0.33 and 0.28), but these
results did not reach statistical difference. There were no sex
or age differences for any of the measures.
Between-group differences
t-tests and ANOVAs with Scheffe´s post hoc tests were used to test
for differences between the three groups on the various
measures. Scores for risk perception and worry were found
to be signiﬁcantly higher (ANOVA: F ¼ 9.4, P < 0.001 and
F ¼ 15.8, P < 0.001) for the group with protein C deﬁciency
compared with the group without protein C deﬁciency and
Table 3 Intercorrelations, means, and SDs for group 3: participants without protein C deﬁciency (n ¼ 58)
Measure Risk perception Worry Trait anxiety Relief Guilty Genetic retest
Risk perception – – – – – –
Worry 0.62* – – – – –
Trait anxiety )0.11 0.10 – – – –
Relief )0.05 0.07 0.07 – – –
Guilty )0.08 0.06 )0.02 0.12 – –
Genetic retest 0.33 0.28 0.00 )0.02 0.14 –
Mean 3.2 3.2 32.5 5.4 1.8 1.7
SD 1.7 1.8 9.4 1.9 1.4 0.8
Range 2–14 2–14 20–80 1–7 1–7 1–7
*P < 0.01.
Table 1 Intercorrelations, means, and SDs, for group 1: participants that had not been tested for protein C deﬁciency (n ¼ 76)
Measure
Risk
perception Worry
Trait
anxiety
Health beneﬁts
beliefs
Psychological
beneﬁts beliefs
Psychological
distress
Testing
interest
Likelihood of
having PC def
Risk perception – – – – – – – –
Worry 0.51* – – – – – – –
Trait anxiety )0.11 )0.01 – – – – – –
Health beneﬁts beliefs 0.21 0.30 )0.08 – – – – –
Psychological beneﬁts beliefs 0.11 0.20 0.13 0.79* – – – –
Psychological distress )0.13 )0.10 0.37* 0.00 0.19 – – –
Testing interest 0.20 0.38* )0.09 0.59* 0.46* )0.13 – –
Likelihood of having PC def 0.40* 0.50* )0.04 0.35* 0.41* 0.01 0.43* –
Mean 3.9 3.4 36.3 20.6 15.1 7.5 4.6 2.6
SD 2.4 1.9 9.6 7.6 6.1 8.4 2.4 1.6
Range 2–14 2–14 20–80 0–30 0–24 0–30 1–7 1–7
*P < 0.01.
Table 2 Intercorrelations, means, and SDs for group 2: participants with protein C deﬁciency (n ¼ 34)
Measure
Risk
perception Worry
Trait
anxiety
Health beneﬁts
beliefs
Psychological
beneﬁts beliefs
Psychological
distress
Risk perception – – – – – –
Worry 0.70* – – – – –
Trait anxiety 0.01 0.28 – – – –
Health beneﬁts beliefs 0.26 0.19 )0.11 – – –
Psychological beneﬁts beliefs 0.04 0.21 0.19 0.60* – –
Psychological distress 0.13 0.52* 0.61* )0.05 0.30 –
Mean 5.4 5.5 32.9 19.4 14.3 5.3
SD 2.9 2.7 9.0 5.8 5.3 6.9
Range 2–14 2–14 20–80 0–30 0–24 0–30
*P < 0.01.
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those who had not been tested before (see Figs 1 and 2).
Surprisingly, scores on the trait form of the STAI were highest
for the group who did not know their protein C status (see
Fig. 3), but this effect did not reach statistical signiﬁcance
(ANOVA: F ¼ 3.2, P ¼ 0.45).
t-tests demonstrate that, for attitudes about genetic
testing, the individuals who had not been tested and
individuals with known protein C deﬁciency did not differ
signiﬁcantly on any of the measures of psychological
distress, psychological beneﬁts and health beneﬁts of receiv-
ing a genetic test result.
Knowledge about other risk factors for venous thrombosis
The risk factors that were believed to be most likely to cause
venous thrombosis by the participants in our sample were lack
of exercise (50% agreed or strongly agreed with the risk factor),
aging (49% agreed or strongly agreed with the risk factor) and
surgery (45% agreed or strongly agreed with the risk factor).
No differences could be detected among the three groups or for
younger and older participants. Women were more likely than
men to agree with the risk factor birth control pills (t ¼ )4.53,
P < 0.001).
To assess whether knowledge about the risk factors for
venous thrombosis was related to perceptions of risk, throm-
bosis-related worry and attitudes about genetic testing, we
calculated correlations between the total knowledge scores and
the other measures. The only signiﬁcant correlation was found
in the group that had not been tested between the knowledge
and thrombosis-related worry scores (r ¼ 0.33, P < 0.01).
Discussion
The results of this family study indicate that asymptomatic
individuals with a family history of venous thrombosis perceive
the psychological and health beneﬁts of getting a genetic test for
protein C deﬁciency as higher than the psychological distress
following the test. Interestingly, it seems that attitudes about
getting the genetic test did not differ signiﬁcantly between the
group with protein C deﬁciency and the group that had not yet
been tested. This indicates that the expectations of the
participants about getting the genetic test were realistic in
terms of their expectations about the potential health and
psychosocial beneﬁts of testing as well as the psychological
distress a positive test result might cause. However, it is possible
that signiﬁcant differences could not be detected because of
the relatively small number of participants in each group.
1 2 3
Group
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
Fig. 1. Means for risk perception with 95% conﬁdence intervals for
means.
1 32
Group
25.0
26.0
27.0
28.0
29.0
30.0
31.0
32.0
33.0
34.0
35.0
36.0
37.0
38.0
39.0
40.0
Fig. 3. Means for trait anxiety with 95% conﬁdence intervals for means.
1 32
Group
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
Fig. 2. Means for thrombosis-related worry with 95% conﬁdence
intervals for means.
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Furthermore, as participants were not recently tested, it is
possible that adverse psychological effects have arisen directly
after receiving the test result but that individuals have adapted
to their condition over the years, by giving the psychological
effects of their condition a different meaning. This effect, which
has been applied to some extent in quality of life research, is
called response shift [21,22]. Therefore, these results should be
taken with some caution.
For participants who had been tested positive for protein C
deﬁciency, trait anxiety was highly correlated to psychological
distress following the genetic test. As the same relationship can
be noted for participants who had not been tested before, it
seems that in general there are few adverse psychological effects
of receiving a positive test result for protein C deﬁciency, but
that certain vulnerable individuals, with a high predisposition
to anxiety, might experience considerable distress following the
positive test result. This is in line with the ﬁndings of Lindqvist
et al. [12] who found that most APC resistant women reported
that their lives were unaffected by the knowledge of being APC
resistant, but that about a quarter of the women became more
worried after getting the test. Additionally, this effect has been
found in earlier research on predictive genetic testing [11]. In
this light, it is also notable that a high score on trait anxiety
does not predict interest in getting the genetic test or a higher
belief in having protein C deﬁciency among the individuals who
have not been tested before. This suggests that a high
dispositional anxiety does not necessarily motivate one to have
a genetic test performed or to believe they have a high
likelihood of having an abnormal result. It is interesting to note
that worry rather than risk perception was the only measure
that correlates with the attitudes about the genetic test and
interest in getting the genetic test. These ﬁndings are consistent
with earlier research byCameron et al. [20] and suggest that it is
not the perception of risk that motivates people to take a
genetic test, but the disease-speciﬁc worry people experience.
As the lifetime risk for venous thrombosis in protein C deﬁcient
individuals is 50%, even the protein C deﬁcient participants in
this study slightly underestimate their risk for venous throm-
bosis. These relatively low risk perceptions could be because of
people’s tendency to underestimate their own risk, also called
optimistic bias [23].
Another interesting ﬁnding is that knowledge of risk factors
for venous thrombosis does not differ between the three
groups. However, only for the group that has not been tested,
knowledge about the other risk factors for venous thrombosis
is related to worry about venous thrombosis. This indicates
that without knowing whether one has protein C deﬁciency or
not, knowledge of other risk factors for venous thrombosis
increases worry and that this knowledge does not inﬂuence
worry in participants who have already been tested.
This study describes the results for the asymptomatic family
members of one kindred only. It is possible that patients who
have experienced an episode of venous thrombosis might react
differently togettingapositive test result forproteinCdeﬁciency
or another form of thrombophilia. Protein C deﬁciency is a
disorder characterized by a 10-fold increased risk of developing
venous thrombosis andmany familymembers have experienced
the episodes of venous thrombosis in a close relative. This likely
explains the fact that many family members consider getting
testedasvery important for their family.Patientswithadifferent
family history of venous thrombosis may express different
emotional reactions to the knowledge of having thrombophilia.
This study was not randomized, so there is a possibility that
participants who decided to get tested differed from the other
participants. In addition, because this is a family study in which
most of the participants had already been tested previously
(mostly around10 years ago for the beneﬁts of an earlier study),
itwasnotpossible toassess the reactions to the test, directly after
receiving the test result. As discussed earlier, it is possible that
adverse psychological effects have arisen directly after receiving
the test result but that individuals have adapted to their
condition over the years because of a response shift. This effect
has been noted in earlier research on hereditary cancer as well
[9,24], and should be acknowledged in further research on the
psychological consequences of genetic testing for thrombo-
philia.
Taking the limitations of this study and their possible effect
on the outcome of this study into account, we can conclude by
saying that there do not seem to be many long-term negative
psychological consequences of genetic testing for thrombo-
philia as measured by thrombosis-related worry and psycho-
logical distress following the test results. However, the
short-term effects of testing deserve more attention in future
studies. Future studies should investigate a more diverse group
of thrombophilia patients with variation in risk factors. Ideally,
such a study would have a randomized longitudinal design,
with measurements of psychological distress immediately after
receiving the test result and at a speciﬁed later time point, to
investigate whether the duration and intensity of the perceived
emotional impact of the test changes over time. In addition, it
would be useful to include measures about state anxiety or
depression following the genetic test result. From a clinical
perspective, this study indicates that genetic testing for protein
C deﬁciency does not have many adverse psychological effects
in the long term.However, it is also important to note that non-
tested individuals from a high-risk family do not worry
excessively about developing venous thrombosis. To make a
fully informed choice about genetic testing for thrombophilia,
it is important that physicians inform patients in great detail
about the other risk factors for venous thrombosis and the lack
of treatment for thrombophilia.
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